

## Bharat Biotech launches India's only vertically integrated cell and gene therapy, viral production facility at Genome Valley

20 March 2025 | News

**This facility ushers in a new era of gene and cell therapies to tackle scientific challenges**



Bharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, has announced the launch of India's only vertically integrated, purpose-designed Cell & Gene Therapy (CGT) Infrastructure & Viral Vector Production Facility at Genome Valley, expanding its expertise from vaccine innovation to leading-edge regenerative and personalised therapies that promise hope for millions.

This facility ushers in a new era of gene and cell therapies to tackle scientific challenges such as targeted gene expression, immune system modulation, and long-term cell survival.

The work will span from boosting immune responses against cancer to ensuring that therapeutic proteins are safely accepted in patients with genetic diseases like hemophilia.

The 50,000-square-foot dedicated state-of-the-art CGT facility represents the next milestone in BBIL's long-standing mission to deliver targeted, life-saving treatments that address unmet clinical needs globally by concentrating on critical conditions such as hematological malignancies and inherited blood disorders.

Outlining the purpose behind establishing India's only vertically integrated cell and gene therapy facility, Dr Krishna Ella,

Executive Chairman, Bharat Biotech said, "Gene and cell therapies represent some of the most intricate, scientifically advanced treatments available today, involving sophisticated processes that require expertise in precise genetic manipulation and specialised manufacturing capabilities."

Multiple specialised teams, spanning process development, production, quality assurance, and quality control, will collaborate under one roof to drive the clinical translation of novel therapies. Full-scale operations are on track to commence as the facility finalises regulatory approvals and completes the remaining build-out phases.